Company Profile
| Company name | Immunomedicine,Inc. |
| Founded date | December 1, 2020 |
| Capital stock | 8.5million yen |
| Directors | CEO Toshihiro Nakajima CSO Yasufumi Kaneda |
| Business Description | Research, development and sales of pharmaceutical products |
| Number of employees | 4（including directors） |
| Head Office | 4-1-3 Bingocho, Chuo-ku, Osaka, 541-0051, Japan Midosuji Mitsui Building, 4th floor, Lifescience HUB West |
| Laboratory | 2-1, Yamadaoka, Suita, Osaka, 565-0871, Japan Osaka University Industry-University-Co-Creation Building A Room302 |
Company History
| December 2020 | Incorated Imuunomedicine, Inc. for the development of immunotherapeutic drugs. |
| February 2020 | Financing through third-party allotment of new shares (15 million yen) |
| March 2020 | Concluded a joint research agreement with Osaka University |
| June 2021 | Concluded a joint research agreement with AnGes, Inc. |
| July 2021 | Head office relocated from Ibaraki City to Osaka City |
| December 2022 | Concluded a joint research agreement with YouJia (HangZhou) Bio-medical Technology Co., Ltd. |
| January 2023 | Started treatment preparation on anticancer drug in China with YouJia (HangZhou) Bio-medical Technology Co.,Ltd (Pre-IND consultation) |
| April 2024 | Won the Grand Prize at The JSSA KANSAI Pitch Award hosted by Japan Startup Support Association, and sponsor awards (Hankyu Hanshin Real Estate and ITOCHU Corporation). |
| August 2024 | Funded by J-KISS |
| April 2025 | Won the Grand Prize at The JSSA Tokyo Pitch Award & Power Matching Booth Vol. 58 hosted by Japan Startup Support Association. |